AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VKTX · NASDAQ · Biotechnology

Viking Therapeutics (VKTX)

Develops clinical-stage therapies for obesity, metabolic and endocrine disorders.

$40.20

vs last close+10.09 (+33.51%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	0
	27	29	34	34	37	46	55	75	99	165	164	133
Research & development	18	21	24	24	23	31	41	60	90	153	150	116
	9	9	10	10	14	15	14	14	9	11	14	17
General & administrative	9	9	10	10	14	15	14	14	9	11	14	17
Operating income	−27	−29	−34	−34	−37	−46	−55	−75	−99	−165	−164	−133
	5	5	7	12	12	11	10	9	8	7	6	5
Interest income	5	5	7	12	12	11	10	9	8	7	6	5
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	0	−5	−7	−12	−12	−11	−10	−9	−8	−7	−6	−5
Income before tax	−23	−25	−27	−22	−25	−35	−46	−66	−91	−158	−158	−128
Net income from continuing operations	−23	−25	−27	−22	−25	−35	−46	−66	−91	−158	−158	−128
Net income	−23	−25	−27	−22	−25	−35	−46	−66	−91	−158	−158	−128
EPS, basic	−$0.23	−$0.25	−$0.26	−$0.20	−$0.22	−$0.32	−$0.41	−$0.58	−$0.81	−$1.38	−$1.37	−$1.10
EPS, diluted	−$0.23	−$0.25	−$0.26	−$0.20	−$0.22	−$0.32	−$0.41	−$0.58	−$0.81	−$1.38	−$1.37	−$1.10
Weighted average shares, basic	100	100	103	110	111	111	112	112	112	114	116	116
Weighted average shares, diluted	100	100	103	110	111	111	112	112	112	114	116	116
EBITDA	−27	−25	−27	−22	−25	−35	−45	−65	−91	−158	−158	−128
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−27	−25	−27	−22	−25	−35	−46	−66	−91	−158	−158	−128